Actionable Insights for Targeted PARPi Therapy
The HRD test evaluates both BRCA1/2 mutations alongside indicators of genomic instability in ovarian cancer. Genomic instability is a hallmark of tumors with impaired DNA repair mechanisms, often resulting in the accumulation of mutations. Based on tumor BRCA1/2 mutation status and a genomic scar score, this test helps predict a tumor’s likelihood of responding to therapies targeting DNA repair deficiencies, such as PARP inhibitors (PARPi).
| BRCA Status | GSS Score | HRD Status |
|---|---|---|
| BRCA +ve | GSS High (≥50) | HRD Positive |
| BRCA +ve | GSS Low (<50) | HRD Positive |
| BRCA -ve | GSS High (≥50) | HRD Positive |
| BRCA -ve | GSS Low (<50) | HRD Negative |
